Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc., as indicated in the metadata request) on November 16, 2018, reporting events occurring on November 14, 2018. The filing announces the release of financial results for the three and nine months ended September 30, 2018, alongside updates on clinical programs and business highlights.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.01), which is incorporated by reference but not detailed in the body of this 8-K form.
Material Changes
No specific material changes versus prior periods are quantified in this document. The filing serves as a notification that results for the three and nine months ended September 30, 2018, have been reported.
Guidance, Outlook, and Risks
The Company provided an update on clinical programs and business highlights in the referenced press release. The filing explicitly states that the information furnished under Item 2.02 and Exhibit 99.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liability of such section, nor is it incorporated by reference into subsequent filings unless specifically stated.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Press Release (Exhibit 99.01) dated November 14, 2018.
- Review the clinical program updates and business highlights detailed in the press release.
- Confirm the legal status of the information, noting that the 8-K itself disclaims liability for the forward-looking statements and data contained in the exhibit.
- Ensure the correct registrant name is Neuralstem, Inc., as the metadata reference to Palisade Bio, Inc. appears to be an error.